← Back to headlines
Gilead Sciences to Acquire ADC Specialist Tubulis for $5 Billion
Gilead Sciences announced its intention to acquire Tubulis, a company specializing in antibody-drug conjugates (ADCs), in a deal valued at $5 billion, expanding its oncology pipeline.
7 Apr, 15:38 — 7 Apr, 15:38
Sources
Showing 1 of 1 sources
